270 related articles for article (PubMed ID: 21953021)
1. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.
Ali HR; Dawson SJ; Blows FM; Provenzano E; Pharoah PD; Caldas C
Br J Cancer; 2012 May; 106(11):1798-806. PubMed ID: 22538974
[TBL] [Abstract][Full Text] [Related]
3. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
[TBL] [Abstract][Full Text] [Related]
5. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.
Dawson SJ; Makretsov N; Blows FM; Driver KE; Provenzano E; Le Quesne J; Baglietto L; Severi G; Giles GG; McLean CA; Callagy G; Green AR; Ellis I; Gelmon K; Turashvili G; Leung S; Aparicio S; Huntsman D; Caldas C; Pharoah P
Br J Cancer; 2010 Aug; 103(5):668-75. PubMed ID: 20664598
[TBL] [Abstract][Full Text] [Related]
6. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.
Callagy GM; Pharoah PD; Pinder SE; Hsu FD; Nielsen TO; Ragaz J; Ellis IO; Huntsman D; Caldas C
Clin Cancer Res; 2006 Apr; 12(8):2468-75. PubMed ID: 16638854
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
11. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance.
Ali HR; Dawson SJ; Blows FM; Provenzano E; Pharoah PD; Caldas C
Breast Cancer Res; 2011; 13(6):R118. PubMed ID: 22112299
[TBL] [Abstract][Full Text] [Related]
13. Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer.
Hwang KT; Kim YA; Kim J; Oh HJ; Park JH; Choi IS; Park JH; Oh S; Chu A; Lee JY; Hwang KR
Sci Rep; 2021 Jun; 11(1):11942. PubMed ID: 34099764
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.
Klintman M; Bendahl PO; Grabau D; Lövgren K; Malmström P; Fernö M;
Mod Pathol; 2010 Feb; 23(2):251-9. PubMed ID: 19935641
[TBL] [Abstract][Full Text] [Related]
15. Bcl2 and Ki67 refine prognostication in luminal breast cancers.
Chen LY; Tsang JY; Ni YB; Chan SK; Chan KF; Zhang S; Tse GM
Breast Cancer Res Treat; 2015 Feb; 149(3):631-43. PubMed ID: 25648135
[TBL] [Abstract][Full Text] [Related]
16. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
[TBL] [Abstract][Full Text] [Related]
17. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
[TBL] [Abstract][Full Text] [Related]
18. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of Ki67 in Chinese women diagnosed with ER
Hu Y; Gu R; Zhao J; Yang Y; Liu F; Jin L; Chen K; Jia H; Wang H; Liu Q; Su F; Jia W
BMC Cancer; 2017 Jan; 17(1):28. PubMed ID: 28061893
[TBL] [Abstract][Full Text] [Related]
20. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.
Millar EK; Graham PH; McNeil CM; Browne L; O'Toole SA; Boulghourjian A; Kearsley JH; Papadatos G; Delaney G; Fox C; Nasser E; Capp A; Sutherland RL
Br J Cancer; 2011 Jul; 105(2):272-80. PubMed ID: 21712826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
